(1) Biozentrum, University of Basel, Klingelbergstrasse 70, Basel, Switzerland;(2) Novartis Institutes for Biomedical Research, Basel, Switzerland
Abstract:
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib. Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users.